Isoplexis
71 articles about Isoplexis
-
IsoPlexis to Present IsoLight® Single-Cell Proteomics Data at ASH 2021 Conference
12/8/2021
IsoPlexis today announced that new data generated on its IsoLight® platform will be presented at the 63rd annual American Society of Hematology (ASH) conference, taking place December 11-13 at the Georgia World Congress Center in Atlanta, Georgia.
-
IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies
11/30/2021
IsoPlexis today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller.
-
IsoPlexis to Participate in the Evercore ISI HealthCONx Conference
11/24/2021
IsoPlexis Corporation today announced the company will be participating virtually in the upcoming Evercore ISI 4th Annual HealthCONx Conference.
-
IsoPlexis' Expanded Cell Therapy Offerings Demonstrated in Nature Medicine Publications
11/18/2021
IsoPlexis Corporation, the leader in functional single-cell proteomics, announced the publication of two high-impact clinical research studies in Nature Medicine.
-
IsoPlexis Bolsters Its Global Operational and Product Support Leadership
11/12/2021
IsoPlexis, the leader in functional single-cell proteomics, announced the appointment of two new leadership positions at the company.
-
IsoPlexis to Present Data at SITC 2021 Connecting Genetic Drivers to Functional Proteomics
11/5/2021
IsoPlexis Corporation today announced that data generated on its IsoLight® and IsoSpark® Platforms will be presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 11th
-
Money on the Move: October 6 – 12
10/13/2021
Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week. -
IsoPlexis Announces Closing of Public Offering - Oct 12, 2021
10/12/2021
IsoPlexis Corporation, a leader in functional single-cell proteomics, announced the closing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.
-
Cognition Therapeutics, Pyxis Oncology and IsoPlexis Corp. all announced IPO plans.
-
IsoPlexis Announces Pricing of Initial Public Offering
10/7/2021
IsoPlexis Corporation, a leader in functional single-cell proteomics, announced the pricing of its initial public offering of 8,333,000 shares of common stock at a public offering price of $15.00 per share.
-
IsoPlexis Appoints Jason Myers to its Board of Directors
9/22/2021
IsoPlexis, a leader in functional single-cell proteomics, today announced the appointment of Dr. Jason Myers to its Board of Directors.
-
IsoPlexis acquires extensive DNA and RNA sequencing portfolio to enable integrated single-cell sequencing and proteomic solutions
5/25/2021
The integration of the sequence of each single cell coupled with IsoPlexis' proprietary functional proteomics accelerates insights into discovery biology & development of advanced medicines
-
IsoPlexis Partners with Bucher Biotec to Expand into Switzerland Market
5/18/2021
IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.
-
IsoPlexis Strengthens Commercial Leadership with the Appointment of Jason Ou as Asia-Pacific General Manager
5/13/2021
IsoPlexis, the leader in single-cell proteomics, announced that Jason Ou has joined the company as General Manager for the Asia-Pacific region.
-
Fierce Medtech Names IsoPlexis as One of its "Fierce 15" Companies of 2020
3/8/2021
IsoPlexis announced that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry.
-
IsoPlexis' IsoSpark Wins 2021 BIG Innovation Award
1/12/2021
IsoPlexis announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
-
IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors
1/7/2021
Funding to accelerate global expansion of installed base and deliver new solutions at the convergence of single-cell biology and proteomics
-
IsoPlexis to Present at Citi's Spotlight on Diagnostics on December 17, 2020
12/8/2020
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Citi's Spotlight on Diagnostics on Thursday, December 17th
-
The Scientist Names IsoPlexis Single Cell Intracellular Proteome a Top 10 Innovation of 2020
12/2/2020
IsoPlexis' Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research
-
IsoPlexis to Present at Evercore ISI's 3rd Annual HealthCONx Conference on December 2, 2020
11/25/2020
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay , will present at Evercore ISI's 3 rd Annual HealthCONx Conference on Wednesday, December 2 nd at 9:40 a.m. ET .